Navigation Links
Hepatitis B Foundation awards UT School of Public Health professor
Date:1/8/2010

HOUSTON (Jan. 8, 2010) R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

"The HBV vaccine, the first cancer vaccine, provides long-term protection against hepatitis B infection, which is responsible for a large proportion of liver cancer in the world. Ultimately, HBV can be eradicated," said Beasley. "This honor from the Hepatitis B Foundation provides another tool to encourage the world to use the vaccine vigorously."

For more than 18 years, Beasley served as dean of the UT School of Public Health. Beasley has pioneered work in perinatal hepatitis B virus transmission, which showed that mother-infant transmission was the most important factor in sustaining hepatitis B virus infection in Asia. He also did the definitive research that proved that hepatitis B causes primary liver cancer and led the global effort to convince the World Health Organization to establish the HBV vaccine as the first human cancer vaccine.

"Dr. Beasley's contributions to understanding the link between hepatitis B and liver cancer have saved thousands of lives. His work not only transformed our understanding of the cause of liver cancer, but then spearheaded the solution through vaccination," said Roberta B. Ness, M.D., dean of the UT School of Public Health. "We are certainly proud to call him one of our own."

This award is the highest scientific honor awarded by the foundation in recognition and appreciation for the research of hepatitis B.


'/>"/>

Contact: Jade Waddy
jade.waddy@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert

Page: 1

Related medicine news :

1. NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus
2. New Hepatitis C Treatment Shows Promise
3. NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is Wake-Up Call for Washington
4. Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US
5. Lloyd Wright's Alternative Medicine Has One of its Hepatitis C Viral Inhibitors Given Boost as Scripps Study Peptides Effectiveness
6. NVHR: New JAMA Article Underscores Urgent Need for Congress to Act on Viral Hepatitis Detection, Management Funding
7. Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
8. African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C
9. Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
10. Hepatitis B does not increase risk for pancreatic cancer
11. Brown & Toland Supports Fight Against Hepatitis B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: